Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Xenon Pharmaceuticals Analyst Ratings
Xenon Pharmaceuticals Resumed With an Outperform at Raymond James
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
Xenon Pharmaceuticals Participates in a Conference Call With JPMorgan
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 47% Undervalued
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
Express News | Xenon Pharmaceuticals Inc. : H.c. Wainwright Initiates Coverage With Buy Rating
Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital Sticks to Its Buy Rating for Xenon (XENE)
Insiders At Xenon Pharmaceuticals Sold US$1.6m In Stock, Alluding To Potential Weakness
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Xenon Pharmaceuticals Appoints New COO
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Express News | Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Express News | Xenon Pharmaceuticals Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
No Data
No Data